These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30878213)

  • 21. [Oral calcimimetics on secondary hyperparathyroidism of uremia.].
    Imanishi Y
    Clin Calcium; 2017; 27(4):561-566. PubMed ID: 28336833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.
    Goodman WG; Hladik GA; Turner SA; Blaisdell PW; Goodkin DA; Liu W; Barri YM; Cohen RM; Coburn JW
    J Am Soc Nephrol; 2002 Apr; 13(4):1017-1024. PubMed ID: 11912261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of calcimimetics in children with normal kidney function.
    VanSickle JS; Srivastava T; Alon US
    Pediatr Nephrol; 2019 Mar; 34(3):413-422. PubMed ID: 29552709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of calcimimetics in uremic patients with secondary hyperparathyroidism: review.
    Ureña P
    Artif Organs; 2003 Sep; 27(9):759-64. PubMed ID: 12940896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future role of calcimimetics in end-stage renal disease.
    Goodman WG; Turner SA
    Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients.
    Walter S; Baruch A; Dong J; Tomlinson JE; Alexander ST; Janes J; Hunter T; Yin Q; Maclean D; Bell G; Mendel DB; Johnson RM; Karim F
    J Pharmacol Exp Ther; 2013 Aug; 346(2):229-40. PubMed ID: 23674604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1.
    Levi R; Ben-Dov IZ; Lavi-Moshayoff V; Dinur M; Martin D; Naveh-Many T; Silver J
    J Am Soc Nephrol; 2006 Jan; 17(1):107-12. PubMed ID: 16291838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
    Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
    Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
    Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
    Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
    Nagano N
    Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.
    Goodman WG
    Pediatr Nephrol; 2003 Dec; 18(12):1206-10. PubMed ID: 14586685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
    Torres PA; De Broe M
    Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism.
    Sugimoto R; Watanabe H; Ikegami K; Enoki Y; Imafuku T; Sakaguchi Y; Murata M; Nishida K; Miyamura S; Ishima Y; Tanaka M; Matsushita K; Komaba H; Fukagawa M; Otagiri M; Maruyama T
    Kidney Int; 2017 Mar; 91(3):658-670. PubMed ID: 27988213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of Parsabiv
    Harada K; Fujioka A; Konno M; Inoue A; Yamada H; Hirota Y
    Eur J Pharmacol; 2019 Jan; 842():139-145. PubMed ID: 30342948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcimimetics and hyperparathyroidism.
    Krebs LJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological regulation of parathyroid hormone secretion.
    Nemeth EF
    Curr Pharm Des; 2002; 8(23):2077-87. PubMed ID: 12171519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.